Company / Cash & Equivalents
Arrowhead Pharmaceuticals Cash & Equivalents History
FY2016-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$184.4M
FY2021
5-year range
$184.4M / $184.4M
FY2017-FY2021
Trend
+28.5%
vs FY2020
Sector context
#94 of 207
Health Care
What the data says
At $184M, Arrowhead Pharmaceuticals's cash & equivalents ranks #94 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 6 years, ranging from $25M in FY2018 to $222M in FY2019.
Based on SEC 10-K filings.
$184M in FY2021 with a 5-year CAGR of +16.7%.
Declined from $222M to $184M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +95.1%
- 5-Year CAGR
- +16.7%
- 10-Year CAGR
- -
Sector benchmark
#94 of 207 in Health CareTop 45% of 207This company $184.4M Sector average $669.5M
▼
-72.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +16.7%, indicating consistent growth.
- In FY2021, cash & equivalents increased 28.5% year-over-year.
- Ranks #94 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $184.4M | +28.5% |
| FY2020 | $143.6M | -35.3% |
| FY2019 | $221.8M | +793.0% |
| FY2018 | $24.8M | -69.4% |
| FY2017 | $81.2M | -4.9% |
| FY2016 | $85.4M | +346.6% |
As of FY2021 · SEC 10-K · Updated Jun 30, 2026